A naturally occurring psychedelic compound studied for medical use
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Health Secretary Kennedy has announced up to $4.9 million to prepare U.S. studies of ibogaine for PTSD in veterans, with safety concerns and regulatory constraints noted; the program aims to accelerate clinical trials while exploring broader uses for addiction.